The U.S. Food and Drug Administration (FDA) has granted marketing authorization to ZYN nicotine pouches, reinforcing tobacco harm reduction (THR) as a key strategy in reducing smoking-related harm. This landmark decision, based on extensive scientific review, leaves Pakistan with little choice but to reconsider its restrictive stance on THR products, given its alarmingly high smoking rates.
With 31 million smokers and over 160,000 smoking-related deaths annually, Pakistan is grappling with a smoking crisis. Existing measures have failed to curb smoking prevalence, and the need for better alternatives has never been more urgent.
“To receive marketing authorizations, the FDA must have sufficient evidence that the new products offer greater benefits to population health than risks,” said Matthew Farrelly, Ph.D., director of the Office of Science in the FDA’s Center for Tobacco Products. “In this case, the data show that these nicotine pouch products meet that bar by benefiting adults who use cigarettes and completely switch to these products.”
Despite the availability of ZYN nicotine pouches in Pakistan, they exist in a regulatory gray area. This lack of clear guidelines leaves consumers uncertain about product quality. A well-defined regulatory framework would enable Pakistan to ensure proper labeling, responsible marketing, and widespread accessibility of ZYN nicotine pouches to adult smokers who could benefit from them.
Without a regulatory framework for THR products, smokers who are unwilling or unable to quit will continue turning to harmful products. By embracing harm reduction strategies and regulating scientifically backed alternatives like ZYN nicotine pouches, Pakistan has a chance to curb its smoking crisis and reduce smoking-related deaths.
